Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,123 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (459)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05564338 | Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma | withdrawn | Phase 3 | 0 | BeiGeneINDUSTRY | 0 | Jun 7, 2023 | clinicaltrials |
| NCT04465734 | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC | withdrawn | Phase 3 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 |
| clinicaltrials |
| NCT04546802 | HepATocellular Cancer Hcv Therapy Study(HATCHeT) | withdrawn | Phase 3 | 0 | Bayside HealthOTHER_GOV | 0 | Sep 14, 2020 | clinicaltrials |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection | withdrawn | Phase 2 / Phase 3 | 0 | Shi MingOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma(LD-FOX4/HCC) | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02534337 | Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT03744247 | Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03791918 | Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT02149771 | Combination Treatment for Advanced Liver Cancer | withdrawn | Phase 3 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 19, 2018 | clinicaltrials |
| NCT03081039 | A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma | withdrawn | Phase 3 | 0 | University of LouisvilleOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT02004210 | A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma | withdrawn | Phase 3 | 0 | Seoul National University HospitalOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT00238160 | Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer | withdrawn | Phase 3 | 0 | Kyoto UniversityOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT01327521 | Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma | withdrawn | Phase 3 | 0 | Albert KoongOTHER | 1 | Jun 11, 2012 | clinicaltrials |
| NCT01318200 | Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) | withdrawn | Phase 3 | 0 | Accuray IncorporatedINDUSTRY | 1 | Feb 20, 2012 | clinicaltrials |
| NCT01245582 | Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients(SECOX) | withdrawn | Phase 3 | 0 | SanofiINDUSTRY | 0 | Nov 9, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jun 7, 2023source: clinicaltrials